PMID- 23497599
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130410
LR  - 20211021
IS  - 2251-6581 (Print)
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 11
IP  - 1
DP  - 2012 Dec 10
TI  - Effects of EPA supplementation on plasma fatty acids composition in 
      hypertriglyceridemic subjects with FABP2 and PPARalpha genotypes.
PG  - 25
LID - 10.1186/2251-6581-11-25 [doi]
AB  - BACKGROUND: Fatty acid binding protein 2 (FABP2) and peroxisome 
      proliferator-activated receptor alpha (PPARalpha) are involved in cellular uptake and 
      metabolism of fatty acids. Polymorphism of FABP2 and PPARalpha may influence plasma 
      levels of fatty acids in those who take supplemental eicosapentaenoic acid (EPA). 
      The purpose of this study was to study the potential associations between the 
      Ala54/Thr polymorphism in FABP2 protein and the Leu162/Val in exon 5 and G/C in 
      intron 7 of PPARalpha with plasma fatty acids composition after EPA supplementation. 
      METHODS: Twenty three FABP2 Ala54 and twenty three Thr54 carriers with 
      hypertriglyceridemia were enrolled in this study. Participants took 2 g of pure 
      EPA daily for 8 wks. Plasma fatty acids composition was determined and changes 
      from the baseline were measured. RESULTS: Although EPA supplementation increased 
      the level of plasma EPA and omega-3 fatty acids in both carriers of FABP2 and PPARalpha 
      genes, these effects were more pronounced in Thr54 and Val162 carriers. EPA 
      supplementation decreased the level of some n-6 fatty acids such as arachidonic 
      acid. CONCLUSION: EPA consumption has more favorable effects on blood n-3 fatty 
      acids and can change the level of plasma n-3 fatty acids, particularly EPA. 
      Because the FABP2 Thr54 polymorphism appears to be prevalent in 
      hypertriglyceridemic subjects, increasing EPA intake in these subjects could be 
      an effective strategy for preventing cardiovascular diseases. Finally, diets and 
      micronutrient recommendations should be individualized for high risk people.
FAU - Pishva, Hamideh
AU  - Pishva H
AD  - Department of cellular, Molecular Nutrition, School of Nutrition Sciences and 
      Dietetics, Tehran University of Medical Sciences, Tehran, Iran. 
      pishvahm@tums.ac.ir.
FAU - Amini, Mohsen
AU  - Amini M
FAU - Eshraghian, Mohammad Reza
AU  - Eshraghian MR
FAU - Hosseini, Saeed
AU  - Hosseini S
FAU - Mahboob, Soltan Ali
AU  - Mahboob SA
LA  - eng
PT  - Journal Article
DEP - 20121210
PL  - Switzerland
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC3620558
EDAT- 2013/03/19 06:00
MHDA- 2013/03/19 06:01
PMCR- 2012/12/10
CRDT- 2013/03/19 06:00
PHST- 2012/07/03 00:00 [received]
PHST- 2012/10/24 00:00 [accepted]
PHST- 2013/03/19 06:00 [entrez]
PHST- 2013/03/19 06:00 [pubmed]
PHST- 2013/03/19 06:01 [medline]
PHST- 2012/12/10 00:00 [pmc-release]
AID - 2251-6581-11-25 [pii]
AID - 10.1186/2251-6581-11-25 [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2012 Dec 10;11(1):25. doi: 10.1186/2251-6581-11-25.